



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: www.shyuanye.com  
邮箱: shyysw@sina.com

产品名称: AP20187

产品别名: B/B Homodimerizer

**生物活性:**

Description	AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.																												
IC <sub>50</sub> & Target	FKBP homodimerizer <sup>[1]</sup>																												
In Vitro	When LNCaP cells are treated with AP20187 (B/B Homodimerizer) (100 nM), ro-iCaspase-9 levels are significantly reduced, and the smaller processed active caspase-9 becomes apparent <sup>[2]</sup> .																												
In Vivo	Real-time PCR analysis shows that AP20187 (B/B Homodimerizer) (0.5 mg/kg, 2 mg/kg, or 5 mg/kg) treatment significantly increases the levels of CHOP mRNA in the CNS of PLP/Fv2E-PERK mice at PID12. AP20187 treatment significantly alleviates EAE-induced myelin damage in these mice. AP20187 (B/B Homodimerizer) treatment significantly reduces the number of degenerating axons and increases the density of axons in the demyelinating lesions in the lumbar spinal cord of PLP/Fv2E-PERK mice[2].																												
Solvent&Solubility	<p><b>In Vitro:</b></p> <p>DMSO : ≥ 57 mg/mL (38.44 mM)</p> <p>* "≥" means soluble, but saturation unknown.</p> <table border="1"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent</th><th>Mass</th><th>Concentration</th><th></th></tr><tr><th></th><th>1 mg</th><th></th><th>5 mg</th><th>10 mg</th></tr></thead><tbody><tr><th>1 mM</th><td>0.6744 mL</td><td></td><td>3.3721 mL</td><td>6.7442 mL</td></tr><tr><th>5 mM</th><td>0.1349 mL</td><td></td><td>0.6744 mL</td><td>1.3488 mL</td></tr><tr><th>10 mM</th><td>0.0674 mL</td><td></td><td>0.3372 mL</td><td>0.6744 mL</td></tr></tbody></table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。</p> <p><b>In Vivo:</b></p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂:</p> <p>——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂: 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline</p> <p>Solubility: ≥ 2.5 mg/mL (1.69 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (1.69 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀; 向上述体系中加入 50 μL Tween-80, 混合均匀; 然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2.请依序添加每种溶剂: 10% DMSO → 90% corn oil</p> <p>Solubility: ≥ 2.5 mg/mL (1.69 mM); Clear solution</p>				Preparing Stock Solutions	Solvent	Mass	Concentration			1 mg		5 mg	10 mg	1 mM	0.6744 mL		3.3721 mL	6.7442 mL	5 mM	0.1349 mL		0.6744 mL	1.3488 mL	10 mM	0.0674 mL		0.3372 mL	0.6744 mL
Preparing Stock Solutions	Solvent	Mass	Concentration																										
		1 mg		5 mg	10 mg																								
1 mM	0.6744 mL		3.3721 mL	6.7442 mL																									
5 mM	0.1349 mL		0.6744 mL	1.3488 mL																									
10 mM	0.0674 mL		0.3372 mL	0.6744 mL																									



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

	<p>此方案可获得 <math>\geq 2.5 \text{ mg/mL}</math> (1.69 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 <math>\mu\text{L}</math> 25.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu\text{L}</math> 玉米油中, 混合均匀。</p>
<b>References</b>	<p>[1]. Ahmed S, et al. Photocleavable dimerizer for the rapid reversal of molecular trap antagonists. <i>J Biol Chem.</i> 2014 Feb 21;289(8):4546-52.</p> <p>[2]. Lin W, et al. Oligodendrocyte-specific activation of PERK signaling protects mice against experimental autoimmune encephalomyelitis. <i>J Neurosci.</i> 2013 Apr 3;33(14):5980-91.</p> <p>[3]. Haas ME, et al. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. <i>Circulation.</i> 2016 Jul 5;134(1):61-72.</p>
<b>实验参考:</b>	
<b>Cell Assay</b>	For the in vitro study, 16 h after ADV infection, cells are treated with R1881 (10 nM), AP20187 (B/B Homodimerizer) (10 nM), both, or neither for 8 h. Cells are then rinsed with PBS and fixed with 4% paraformaldehyde for 1 h at room temperature. After rinsing with PBS, cells are incubated in ice-cold permeabilization solution (0.1% Triton X-100, 0.1% sodium citrate) for 2 min at 0°C. Cells are rinsed with PBS and stained with TUNEL reaction mixture for 60 min at 37°C. After another PBS wash, cells are incubated with Converter-AP for 30 min at 37°C. Cells are rinsed and incubated with substrate 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium for 30 min. After a final PBS rinse (repeated twice), cells are microphotographed[2].
<b>Animal Administration</b>	Mice[2]  To activate the transgene Fv2E-PERK in oligodendrocytes, PLP/Fv2E-PERK transgenic mice are given intraperitoneal injections of AP20187 (B/B Homodimerizer) daily at a dose of 0.5 mg/kg, 2 mg/kg, or 5 mg/kg. Lyophilized AP20187 (B/B Homodimerizer) is dissolved in 100% ethanol at a concentration of 62.5 mg/mL stock solution and stored at -20°C. Injection solutions consist of 4% ethanol, 10% PEG-400, and 2% Tween-20 in water. The transgenic mice receiving only the vehicle (4% ethanol, 10% PEG-400, 2% Tween-20 in water) served as controls.
<b>References</b>	<p>[1]. Ahmed S, et al. Photocleavable dimerizer for the rapid reversal of molecular trap antagonists. <i>J Biol Chem.</i> 2014 Feb 21;289(8):4546-52.</p> <p>[2]. Lin W, et al. Oligodendrocyte-specific activation of PERK signaling protects mice against experimental autoimmune encephalomyelitis. <i>J Neurosci.</i> 2013 Apr 3;33(14):5980-91.</p> <p>[3]. Haas ME, et al. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. <i>Circulation.</i> 2016 Jul 5;134(1):61-72.</p>